Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients - 12/05/18
Abstract |
Background |
Dermatologic conditions cause morbidity and mortality among hospitalized cancer patients. An improved understanding is critical for implementing clinical and research programs in inpatient oncodermatology.
Objective |
To characterize inpatient dermatology consultations at a large comprehensive cancer center.
Methods |
Retrospective database query of new admissions and medical record review of initial inpatient dermatology consultations comparing inpatients consulted and not consulted during January-December 2015.
Results |
In total, 412 of 11,533 inpatients received 471 dermatology consultations (54% male, median age 59.5 years). Patients with hematologic cancers were 6 times more likely to receive dermatologic consultations compared with nonhematologic cancers (odds ratio 6.56, 95% confidence interval 5.35-8.05, P < .0001). Patients consulted by a dermatologist had a significantly longer length of stay than inpatients not consulted by dermatology (median 11 vs 5 days, P < .0001). Among the 645 dermatologic conditions diagnosed, the most common categories were inflammatory diseases, infections, and drug reactions; the most frequent conditions were contact dermatitis, herpes zoster, and chemotherapy-induced drug eruptions.
Limitations |
The study's retrospective nature and single-institution setting are potential limitations.
Conclusion |
Hematologic malignancies are a significant risk factor for dermatology inpatient consultations. A significantly longer length of stay was associated with dermatology consultations, suggesting high comorbidities in these patients. Increased dermatologic care of these inpatients might improve quality of life, dermatologic health, and ability to receive anticancer agents.
Le texte complet de cet article est disponible en PDF.Key words : adverse event, cancer, consultation, hematologic, infection, inflammatory, inpatient, oncodermatology, referral
Abbreviations used : dAE, IQR, LOS, MSK
Plan
| Funding sources: Supported in part through the National Institutes of Health National Cancer Institute Cancer Center Support Grant P30 CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was additionally funded in part by Beca Excelencia Fundación Piel Sana (Dr Freites-Martinez). The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript. |
|
| Conflicts of interest: Dr Lacouture has consultant and advisory board roles for Quintiles, AstraZeneca Pharmaceuticals, Legacy Healthcare, Foamix, Janssen R&D, Novocure, and Adgero Bio Pharmaceutical and receives research funding from Berg and Bristol-Myers Squibb. Ms Ciccolini has affiliations with Amgen, P-Value Communication, Roche, and Eaisi Inc. Other authors have no conflicts of interest to disclose. |
Vol 78 - N° 6
P. 1102-1109 - juin 2018 Retour au numéro
Article précédent
- Dermatologic manifestations of solid organ transplantation–associated graft-versus-host disease: A systematic review
- Grace Y. Kim, Leah A. Schmelkin, Mark D.P. Davis, Rokea A. el-Azhary, Ann M. Farrell, Alexander Meves, Julia S. Lehman
- A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon
- Paul Curtiss, Zachary Schwager, Gabriela Cobos, Kristen Lo Sicco, Andrew G. Franks
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?